|
1
|
Wingo PA, Ries LA, Rosenberg HM, Miller DS
and Edwards BK: Cancer incidence and mortality. 1973-1995, a report
card for the U.S. Cancer. 82:1197–1207. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coburn SB, Bray F, Sherman ME and Trabert
B: International patterns and trends in ovarian cancer incidence,
overall and by histologic subtype. Int J Cancer. 140:2451–2460.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jelovac D and Armstrong DK: Recent
progress in the diagnosis and treatment of ovarian cancer. CA
Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oza AM, Cook AD, Pfisterer J, Embleton A,
Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P,
Cervantes A, et al: Standard chemotherapy with or without
bevacizumab for women with newly diagnosed ovarian cancer (ICON7):
Overall survival results of a phase 3 randomised trial. Lancet
Oncol. 16:928–936. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coleman RL, Monk BJ, Sood AK and Herzog
TJ: Latest research and treatment of advanced-stage epithelial
ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Barnholtz-Sloan JS, Schwartz AG, Qureshi
F, Jacques S, Malone J and Munkarah AR: Ovarian cancer: Changes in
patterns at diagnosis and relative survival over the last three
decades. Am J Obstet Gynecol. 189:1120–1127. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sahab ZJ, Hall MD, Me Sung Y,
Dakshanamurthy S, Ji Y, Kumar D and Byers SW: Tumor suppressor
RARRES1 interacts with cytoplasmic carboxypeptidase AGBL2 to
regulate the α-tubulin tyrosination cycle. Cancer Res.
71:1219–1228. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
de Forges H, Bouissou A and Perez F:
Interplay between microtubule dynamics and intracellular
organization. Int J Biochem Cell Biol. 44:266–274. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Song Y and Brady ST: Post-translational
modifications of tubulin: Pathways to functional diversity of
microtubules. Trends Cell Biol. 25:125–136. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Webster DR, Gundersen GG, Bulinski JC and
Borisy GG: Differential turnover of tyrosinated and detyrosinated
microtubules. Proc Natl Acad Sci USA. 84:9040–9044. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kato C, Miyazaki K, Nakagawa A, Ohira M,
Nakamura Y, Ozaki T, Imai T and Nakagawara A: Low expression of
human tubulin tyrosine ligase and suppressed tubulin
tyrosination/detyrosination cycle are associated with impaired
neuronal differentiation in neuroblastomas with poor prognosis. Int
J Cancer. 112:365–375. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mialhe A, Lafanechère L, Treilleux I,
Peloux N, Dumontet C, Brémond A, Panh MH, Payan R, Wehland J,
Margolis RL and Job D: Tubulin detyrosination is a frequent
occurrence in breast cancers of poor prognosis. Cancer Res.
61:5024–5027. 2001.PubMed/NCBI
|
|
14
|
Soucek K, Kamaid A, Phung AD, Kubala L,
Bulinski JC, Harper RW and Eiserich JP: Normal and prostate cancer
cells display distinct molecular profiles of alpha-tubulin
posttranslational modifications. Prostate. 66:954–965. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Whipple RA, Matrone MA, Cho EH, Balzer EM,
Vitolo MI, Yoon JR, Ioffe OB, Tuttle KC, Yang J and Martin SS:
Epithelial-to-mesenchymal transition promotes tubulin
detyrosination and microtentacles that enhance endothelial
engagement. Cancer Res. 70:8127–8137. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Whipple RA, Balzer EM, Cho EH, Matrone MA,
Yoon JR and Martin SS: Vimentin filaments support extension of
tubulin-based microtentacles in detached breast tumor cells. Cancer
Res. 68:5678–5688. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gundersen GG and Bulinski JC: Selective
stabilization of microtubules oriented toward the direction of cell
migration. Proc Natl Acad Sci USA. 85:5946–5950. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang LL, Jin XH, Cai MY, Li HG, Chen JW,
Wang FW, Wang CY, Hu WW, Liu F and Xie D: AGBL2 promotes cancer
cell growth through IRGM-regulated autophagy and enhanced Aurora A
activity in hepatocellular carcinoma. Cancer Lett. 414:71–80. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang H, Ren Y, Pang D and Liu C: Clinical
implications of AGBL2 expression and its inhibitor latexin in
breast cancer. World J Surg Oncol. 12:1422014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang GF, Li XM and Xie D: Overexpression
of clusterin in ovarian cancer is correlated with impaired
survival. Int J Gynecol Cancer. 19:1342–1346. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He WP, Zhou J, Cai MY, Xiao XS, Liao YJ,
Kung HF, Guan XY, Xie D and Yang GF: CHD1L protein is overexpressed
in human ovarian carcinomas and is a novel predictive biomarker for
patients survival. BMC Cancer. 12:4372012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu L, Li X, Cai M, Chen J, Li X, Wu WK,
Kang W, Tong J, To KF, Guan XY, et al: Increased expression of
Solute carrier family 12 member 5 via gene amplification
contributes to tumour progression and metastasis and associates
with poor survival in colorectal cancer. Gut. 65:635–646. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lu Z, Yang H, Sutton MN, Yang M, Clarke
CH, Liao WS and Bast RC Jr: ARHI (DIRAS3) induces autophagy in
ovarian cancer cells by downregulating the epidermal growth factor
receptor, inhibiting PI3K and Ras/MAP signaling and activating the
FOXo3a-mediated induction of Rab7. Cell Death Differ. 21:1275–1289.
2014. View Article : Google Scholar : PubMed/NCBI
|
